American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors
Debbie Saslow(American Cancer Society), Philip E. Castle(National Cancer Institute), J. Thomas Cox(University of California, Santa Barbara), Diane D. Davey(University of Kentucky), Mark H. Einstein(Albert Einstein College of Medicine), Daron G. Ferris(Augusta University), S. J. Goldie(Decision Sciences (United States)), Diane M. Harper(Dartmouth College), Walter Kinney(Gynecologic Oncology Group), Anna‐Barbara Moscicki(University of California, San Francisco), Kenneth L. Noller(Tufts Medical Center), Cosette M. Wheeler(University of New Mexico), Terri B. Ades(American Cancer Society), Kimberly Andrews(American Cancer Society), Mary Doroshenk(American Cancer Society), KL Kahn(American Cancer Society), Christy Schmidt(American Cancer Society), Omar Shafey(American Cancer Society), Robert A. Smith(American Cancer Society), Edward E. Partridge(University of Alabama at Birmingham), (for The Gynecologic Cancer Advisory Group)(Arizona Science Center), F. Garcia(Arizona Science Center)
Cited by 527Open Access
Abstract
The American Cancer Society (ACS) has developed guidelines for the use of the prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical intraepithelial neoplasia and cervical cancer. These recommendations are based on a formal review of the available evidence. They address the use of prophylactic HPV vaccines, including who should be vaccinated and at what age, as well as a summary of policy and implementation issues. Implications for screening are also discussed.
Related Papers
No related papers found
Powered by citation graph analysis